meerecompany Announces Second Export of ‘Revo-i’ to Mongolia
- Supply to Mongolia’s largest tertiary general hospital and expanding clinical application to the field of organ transplantation.
- Consecutive supply to key national hospitals in cancer and organ transplantation fields, strengthens market presence in Mongolia.
meerecompany has announced that it has completed its second export of its surgical robot, Revo-i, to Mongolia. The recipient of this supply is The First Central Hospital of Mongolia, located in the Sukhbaatar District of Ulaanbaatar, Mongolia.
The First Central Hospital of Mongolia is a tertiary general hospital with a capacity of 568 beds and stands as one of the largest national hospitals in Mongolia. It is a representative medical institution that performs various high-difficulty surgeries, with a central focus on the field of organ transplantation
This supply marks the second export case of Revo-i, following its introduction at the National Cancer Center of Mongolia. While the National Cancer Center of Mongolia serves as a base hospital specializing in cancer treatment, The First Central Hospital is a leading medical institution in the field of organ transplantation. By supplying Revo-i to key medical institutions in different specialized medical fields, meerecompany has successfully built clinical references that encompass both cancer surgery and organ transplantation.
Viewing Mongolia as a crucial overseas market, meerecompany has been continuously expanding its local cooperative network, encompassing the government, medical institutions, and academic societies.
In March 2025, the company signed a Memorandum of Understanding (MOU) with the Health Development Center under the Mongolian Ministry of Health to cooperate on improving the Mongolian healthcare system. Following this, in May of this year, it signed an MOU with the Mongolian Federation of Obstetrics and Gynecology, laying the groundwork for robotic surgery education and academic exchange.
In addition, the company participated in the International Congress of Organ Transplant (ICOT 2026) held in Mongolia from June 5 to 6. Through this event, meerecompany introduced Revo-i and expanded exchanges with local medical professionals, actively promoting the applicability of robotic surgery in the field of organ transplantation. Ho Kun Lee, Executive Vice President and Head of the Surgical Robot Division at meerecompany stated, “This supply is highly significant in that we have consecutively supplied Revo-i to Mongolia’s key national hospitals representing the fields of cancer and organ transplantation.” He added, “We expect this to serve as an opportunity to once again prove Revo-i’s technological prowess and clinical competitiveness while further strengthening our presence in the Mongolian market.”
He further noted, “The clinical experience accumulated in major national hospitals will become an important reference not only for expanding the local market in the future but also for entering neighboring markets.” He concluded, “We will continue to contribute to the development of local medical technology based on close cooperation with the Mongolian government and major medical institutions, while consistently expanding our global business.”
Source: meerecompany
